W. N. Brennen, Ph.D.
Affiliations: | 2011 | Johns Hopkins University, Baltimore, MD |
Area:
Pharmacology, Medicine and Surgery, Molecular Biology, OncologyGoogle:
"W. Brennen"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Samuel R. Denmeade | grad student | 2011 | Johns Hopkins | |
| (Targeting carcinoma-associated fibroblasts (CAFs) with a fibroblast activation protein (FAP)-activated prodrug chemotherapy.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Caramella-Pereira F, Zheng Q, Hicks JL, et al. (2025) Overexpression of fibroblast activation protein (FAP) in the stroma of proliferative inflammatory atrophy (PIA) and primary adenocarcinoma of the prostate. Pathology |
| Nouri M, Varkaris A, Ridinger M, et al. (2024) AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate Cancer. Molecular Cancer Therapeutics |
| Caramella-Pereira F, Zheng Q, Hicks JL, et al. (2024) Overexpression of Fibroblast Activation Protein (FAP) in stroma of proliferative inflammatory atrophy (PIA) and primary adenocarcinoma of the prostate. Medrxiv : the Preprint Server For Health Sciences |
| Pacheco-Torres J, Sharma RK, Mironchik Y, et al. (2024) Prostate fibroblasts and prostate cancer associated fibroblasts exhibit different metabolic, matrix degradation and PD-L1 expression responses to hypoxia. Frontiers in Molecular Biosciences. 11: 1354076 |
| Brennen WN, Le Magnen C, Karkampouna S, et al. (2024) Defining the challenges and opportunities for using patient-derived models in prostate cancer research. The Prostate |
| Mandl A, Jasmine S, Krueger T, et al. (2024) LSD1 inhibition suppresses ASCL1 and de-represses YAP1 to drive potent activity against neuroendocrine prostate cancer. Biorxiv : the Preprint Server For Biology |
| Mori JO, Elhussin I, Brennen WN, et al. (2023) Prognostic and therapeutic potential of senescent stromal fibroblasts in prostate cancer. Nature Reviews. Urology |
| Patel RA, Sayar E, Coleman I, et al. (2023) Characterization of HOXB13 expression patterns in localized and metastatic castration-resistant prostate cancer. The Journal of Pathology |
| Labrecque MP, Brown LG, Coleman IM, et al. (2023) Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer. The Prostate |
| Isaacs JT, Dalrymple SL, Antony L, et al. (2023) Third generation quinoline-3-carboxamide transcriptional disrupter of HDAC4, HIF-1α, and MEF-2 signaling for metastatic castration-resistant prostate cancer. The Prostate |